Much recent research has focused on the use of
monoclonal antibodies (MAbs) in the immunodetection of solid
tumors.
Fab fragments of MAbs are more suitable for immunoscintigraphy than intact MAbs. Recently, human-mouse chimeric
antibodies have been developed in an effort to reduce human antimouse antibody (HAMA) production by murine MAbs in humans. In this study, 125I-labeled murine and chimeric
Fab fragments of the MAb A7 were injected i.v. into nude mice bearing a human
pancreatic cancer (HPC-YS) xenograft. The radioactivity in
tumors and in normal tissues was subsequently measured. The
tumor tissue/blood ratio (T/B) of 125I-labeled murine and chimeric
Fab fragments of MAb A7 increased with time in a similar manner and reached 9.68 +/- 2.54 and 10.49 +/- 1.50, respectively, 24 h after injection. Moreover, the T/Bs of 125I-labeled murine and chimeric
Fab fragments of MAb A7 were greater than the T/B of intact MAb A7. When mice bearing
tumors that did not react with MAb A7 were studied, 125I-labeled murine and chimeric
Fab fragments did not localize specifically to the
tumors. These results suggests that chimeric
Fab fragments of MAb A7 are useful carriers of
radionuclides for the immunodetection of human
pancreatic cancer, with equivalent activity to murine
Fab fragments and less theoretical potential to induce a HAMA response.